Form of presentation | Conference proceedings in international journals and collections |
Year of publication | 2017 |
|
Kiseleva Anna Alekseevna, author
|
|
Kiseleva Anna Alekseevna, postgraduate kfu
|
Bibliographic description in the original language |
The primary cilium is an antenna-like structure protruding from the cell
surface, which provides a platform for receptors for signaling systems including
PDGF-alpha, Hedgehog, Wnt, and others that influence cell differentiation and
proliferation decisions. Under normal physiological growth conditions, the cilium
forms after mitosis and in quiescent cells, extending from a basal body
centered at a centriole, with timed resorption in G0 or early G1. Cancer cells
have altered ciliary dynamics, with some (medulloblastomas and basal cell carcinomas)
often dependent on cilia, and other tumor types downregulating them.
In prior work, we defıned Aurora-A, an oncogenic kinase typically thought of as
a mitotic regulator, as transiently activated at the basal body, and absolutely
required for resorption of cilia at the G0/G1 boundary, and we showed the
targeted Aurora-A inhibitor entirely blocked ciliary resorption. In subsequent
work, we found that a second drug, the EGFR inhibitor erlotinib, al |
Keywords |
primary cilium, ALisertib, Sunitinib |
Place of publication |
Washington DC |
Publishing house |
AACR |
URL |
http://www.aacr.org/Meetings/Pages/MeetingDetail.aspx?EventItemID=105&DetailItemID=539&utm_source=social&utm_medium=twitter&utm_content=am17&utm_campaign=annual-meeting#.WU-7Amg19PY |
Please use this ID to quote from or refer to the card |
https://repository.kpfu.ru/eng/?p_id=160420&p_lang=2 |
Full metadata record |
Field DC |
Value |
Language |
dc.contributor.author |
Kiseleva Anna Alekseevna |
ru_RU |
dc.contributor.author |
Kiseleva Anna Alekseevna |
ru_RU |
dc.date.accessioned |
2017-01-01T00:00:00Z |
ru_RU |
dc.date.available |
2017-01-01T00:00:00Z |
ru_RU |
dc.date.issued |
2017 |
ru_RU |
dc.identifier.citation |
The primary cilium is an antenna-like structure protruding from the cell
surface, which provides a platform for receptors for signaling systems including
PDGF-alpha, Hedgehog, Wnt, and others that influence cell differentiation and
proliferation decisions. Under normal physiological growth conditions, the cilium
forms after mitosis and in quiescent cells, extending from a basal body
centered at a centriole, with timed resorption in G0 or early G1. Cancer cells
have altered ciliary dynamics, with some (medulloblastomas and basal cell carcinomas)
often dependent on cilia, and other tumor types downregulating them.
In prior work, we defıned Aurora-A, an oncogenic kinase typically thought of as
a mitotic regulator, as transiently activated at the basal body, and absolutely
required for resorption of cilia at the G0/G1 boundary, and we showed the
targeted Aurora-A inhibitor entirely blocked ciliary resorption. In subsequent
work, we found that a second drug, the EGFR inhibitor erlotinib, al |
ru_RU |
dc.identifier.uri |
https://repository.kpfu.ru/eng/?p_id=160420&p_lang=2 |
ru_RU |
dc.language.iso |
ru |
ru_RU |
dc.publisher |
AACR |
ru_RU |
dc.subject |
primary cilium |
ru_RU |
dc.subject |
ALisertib |
ru_RU |
dc.subject |
Sunitinib |
ru_RU |
dc.title |
Unexpected activity of multiple targeted cancer drugs in regulating ciliary dynamics |
ru_RU |
dc.type |
Conference proceedings in international journals and collections |
ru_RU |
|